Acute Interstitial Lung Disease Induced by Rechallenge with Ceritinib

A 40-year-old Japanese man with advanced pulmonary adenocarcinoma harboring anaplastic lymphoma kinase (ALK)-rearranged was administered the selective ALK inhibitor ceritinib as a third-line treatment and continued treatment for nine months. After fourth-line treatment, we performed rechallenge with...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2020/01/15, Vol.59(2), pp.253-256
Main Authors: Hotta, Takamasa, Okimoto, Tamio, Hamaguchi, Megumi, Tsubata, Yukari, Isobe, Takeshi
Format: Article
Language:English
Subjects:
Adenocarcinoma
adverse event
anaplastic lymphoma kinase
Case Report
ceritinib
Computed tomography
Dyspnea
Internal medicine
interstitial lung disease
Lung diseases
Methylprednisolone
Protein-tyrosine kinase
Respiration
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 40-year-old Japanese man with advanced pulmonary adenocarcinoma harboring anaplastic lymphoma kinase (ALK)-rearranged was administered the selective ALK inhibitor ceritinib as a third-line treatment and continued treatment for nine months. After fourth-line treatment, we performed rechallenge with ceritinib as a fifth-line treatment. On day 54 after rechallenge, the patient developed acutely deteriorating dyspnea. Chest computed tomography showed extensive ground-glass opacities. We diagnosed him with ceritinib-induced interstitial lung disease (ILD) and initiated methylprednisolone pulse therapy. To our knowledge, this is the first report of ceritinib-induced ILD in a Japanese patient. Since it may newly emerge with rechallenge therapy, close attention is necessary.
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.2597-18